Phanes Therapeutics, Inc.

Phanes Therapeutics, Inc. is a clinical-stage biotechnology company based in San Diego, California. Founded in July 2016, the company focuses on innovative drug discovery and early development, primarily in immuno-oncology, while also addressing eye diseases, cancer, and metabolic complications. The team is led by Dr. Ming Wang, who has extensive experience in the pharmaceutical industry.

Phanes is dedicated to advancing therapeutic molecules through its proprietary technology platforms, which include PACbody™, ATACCbody™, and SPECpair™. These platforms are designed to enhance the properties and manufacturability of bispecific antibodies. The company is currently developing monoclonal and bispecific antibodies aimed at improving immune responses against cancer cells and is actively involved in clinical studies, including the recent dosing of the first patient with PT886 in combination with chemotherapy. With a strong pipeline and a mission to drive biopharma innovation, Phanes Therapeutics is positioned to make significant contributions to the field.